We determined the circulating level of bioactivity for skeletal muscle proteolysis-inducing factors (PIF) 
Summary
We determined the circulating level of bioactivity for skeletal muscle proteolysis-inducing factors (PIF) in the blood samples from cancer patients whose body weight loss was greater than 10%. The level of bioactivity was estimated by measurement of tyrosine release from isolated rat diagphragm muscles incubated with an ultrafiltered fraction of plasma or serum proteins containing molecules from 0 to 25 kDa in molecular weight. Significant levels of bioactivity were detected in 25 of the 50 cancer samples. No activity was found in 18 of the samples from healthy human blood donors. The ability of 13 of the cancer samples to induce muscle proteolysis was significantly inhibited by incubation of muscles in presence of indomethacin (10 gM). The neutralisation of 12 of the cancer samples with the antibodies to recombinant human interleukin-I (IL-1), a and P forms, partially abrogated the activity in five samples. These results suggest that the accelerated breakdown of proteins induced by the cancer plasma factors is at least in part mediated by IL-1 in cooperation with other active factors not yet defined. Additionally, we have shown that the increased breakdown of proteins induced by PIF in the crude supernatant derived from activated mouse peritoneal macrophages is prevented by the treatment of muscles with either indomethacin or quin-2 (1 juM). These observations provide indirect evidence for a possible causal relationship between the production of PIF and the body-weight loss of cancer patients.
The loss of body weight and development of cachexia are common and easily recognisable signs that are associated with cancer and several other chronic and inflammatory diseases (Lawson et al., 1982) . In response to neoplastic and infectious diseases, a variety of cells, including macrophages and lymphocytes, secrete cytokines which are capable of altering the host's metabolism. These cytokines include interleukin-1 (IL-1) (Dinarello, 1988) and tumour necrosis factor/cachetin (TNF-a) (Beutler & Cerami, 1986) . TNF-a has been suggested to contribute to the development of the complex metabolic changes leading to cachexia because it suppresses lipoprotein lipase activity (Kawakami & Cerami, 1981; Semb et al., 1987) ; and rodents given daily injections of this cytokine (Stovroff et al., 1988; Tracey et al., 1988) , or inoculated with a TNF/cachectinsecreting tumour (Oliff et al., 1987) progressively decline food intake and develop severe body wasting. Recent studies have revealed that mobilisation of amino acids from skeletal muscle tissue of patients undergoing infectious illness, trauma or sepsis is mediated by a hormone-like protein called proteolysis-inducing factor (PIF) (Clowes et al., 1983) . This protein secreted by activated monocytes may be IL-1 or a IL-i-like peptide (Baracos et al., 1983; Dinarello et al., 1984) . It has also been shown that prostaglandin E2 production was increased by these macrophage secretory products and an inhibitor of the cycloocygenase pathway, indomethacin, partially attenuated the stimulation in skeletal muscle protein degradation (Baracos et al., 1983 (Moldawer et al., 1987; Goldberg et al., 1988) . Likewise, the involvement of TNF-a on catabolism of proteins has been demonstrated by some studies in vivo (Warren et al., 1987; Flores et al., 1989; Fong et al., 1989) and in vitro Charters & Grimble, 1989) and refuted in others (Kettelhutt & Goldberg, 1988; Moldawer et al., 1987; Rofe et al., 1987; Michie et al., 1988) . Nevertheless, the capacity of IL-1 and TNF to cause either weight loss or anorexia in animals has often been noted (Stovroff et al., 1988; Hellestein et al., 1989; Fong et al., 1989; Michie et al., 1988; (Dinarello et al., 1986a) , and polyclonal rabbit anti-sera to rhIL-1-a and rhIL-1-P (Dinarello et al., 1986b) were generously provided by Dr Charles A. Dinarello, Tufts University/New England Medical Center (Boston, MA). To neutralise IL-1 activity, the mixture of antibodies to IL-1-< and IL-1-P (final concentration of each one 0.05%) plus the serum/plasma samples were incubated at 4°C for 24 h. One control assay was carried out using rabbit nonimmune sera.
Net protein catabolism assay in the rat diaphragm muscle Following anaesthesia (ether), rats were killed by cervical dislocation. Both hemidiaphragm muscles (lacking ribs) were promptly dissected and cut into two pieces (one used in paired control and the other in a test assay). Each quarter of muscle was rinsed, blotted, weighted (30-40 mg), and placed into a stoppered borosilicate glass flask (15 ml size) containing 1.5 ml of Krebs-Ringer-Bicarbonate buffer, pH 7.4, supplemented with glucose 5 mM, branched chain amino acids [0.85 mM isoleucine, 0.5 mM leucine and 1 mM valine], insulin 0.1 Uml', HEPES 15mM, polymyxin B 201tgml-', and equilibrated with a 95% 02/5% CO2 gas mixture. The muscles were pre-incubated for 1 h at 37°C in a shaking water bath. Thereafter, they were transferred into fresh media containing either crude supernatants from macrophage culture, low molecular weight fraction of human serum/plasma proteins, or recombinant human IL-1 proteins, and incubated for further 2 h. The conditioned media were analysed for tyrosine concentration according to the fluorometric method of Waalkes and Undernfriend (1957) . The results were expressed as pM of tyrosine per mg of muscle tissue (wet weight) per 2 h. In the cancer samples assays, the net protein catabolism was calculated as the difference between the total of tyrosine released into the incubating medium and the initial tyrosine content into the plasma samples, determined in a separate test-tube. The net protein catabolism rate to each particular sample (average of six replicates) was compared with the paired control and the result expressed as the difference (A) between the means ± s.e.m. (Figures 2, 3 and 4). In the assay to examine IL-1 activity, 1.0% FCS was added to the incubation buffer to prevent protein adherence to the glass.
Isolation and culture ofperitoneal macrophages and preparation of crude supernatants
The peritoneal leukocytes were harvested from the mouse cavity after injection of 10ml RPMI 1640 medium (Gibco Laboratories, Grand Island, NY). The cell suspension was washed in culture medium and collected by centrifugation at 800 g for 15 min. The cell pellet was diluted in RPMI medium that contained 10% foetal calf serum (FCS) and antibiotics and approximately 5 x 106 cells ml-1 were inoculated into 24-well microplates at a volume of 0.5 ml per well and incubated in a humidified CO2 incubator at 37°C for 4 h. The non-adherent cells were removed by gently rinsing the wells with medium and the adherent cells were subsequently incubated overnight in complete medium. The next day, the medium was aspirated and fresh medium containing 1 jigml-' LPS (LPS E. coil 055:B5, Sigma) or 10ngml-' PMA (Phorbol 12-myristate 13-acetate-4-O-methyl ether, Sigma) were added and cells returned to incubator for an additional 24 h. Parallel control cultures were performed in which only complete medium was added. The culture media were collected, centrifuged and the cell-free supernatant stored at -70°C until analysis.
Other assays TNF content in the crude supernatants from activated macrophages and in a low molecular weight fraction of plasma proteins from cancer patients were assayed using the L929 mouse fibroblast cell cytotoxicity assay (Flick & Gifford, 1984) . Briefly, approximately 50 x 104 L929 cells ml-' were suspended in culture medium and dispensed into 96-well microtitre plates, and grown overnight at 37°C in a 5% C02-95% air atmosphere. Subsequently, the media were removed and replaced with RPMI 1640 containing 2.5% FCS, supplemented with 5 iLg ml-' of actinomycin D (control) or serial dilutions of rhTNF (kindly provided by Genentech Inc., South San Francisco, CA) or the test samples. The plates were incubated for a further 18 -20 h. Viability of cells was measured by staining for 3-4 h with 500 pg ml-' of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (Sigma), followed by removal of medium and lysis of cells with 0.1 ml isopropanol. The photometric measurement was performed at 560/690 nm in a Bio-Rad model 3550 microplate reader. The TNF-a content in a sample, expressed in U ml-', was calculated by com- parison to a calibration curve established with rhTNFa. One unit of TNF was defined as the concentration of TNF necessary to achieve 50% cell cytotoxicity. IL-1-P and TNF-x were also determined by a radioimmunoassay as described elsewhere (Endress et al., 1988) .
Statistics
All data are expressed as mean ± s.e.m.. Differences in the tyrosine release between experimental groups were evaluated using the Student's t-test for unpaired comparisons. The standard error of the difference between the groups was determined by the formula: s.e.m. = square root (s.d.,2/ n, + s.d.22/n2).
Results
Effects of a low molecular weight fraction of the human plasma or serum proteins on the rat diaphragm muscle net protein catabolism For comparison, in Figure 1 we show the effects induced by the addition of a low molecular weight fraction, which con-tain molecules ranging from 0 to approximately 25,000 molecular weight, derived from plasma or serum samples of a group of 18 normal subjects and a group of 50 cancer patients on net protein catabolism of the rat diaphragm muscles. As seen in Figure 1 
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Values are the means ± s.e.m. for sextuplicates incubating from one of three similar experiments. Indomethacin (1O pM) and quin-2 (I FM) were added in both pre-incubation and incubation media. 'The effect of quin-2 and related assays were examined in the final I h of incubation. The crude supernantant obtained from PMA-stimulated mice peritoneal macrophage culture were added to incubation buffer at a dilution 1:10. *P <0.05 vs paired control. enhancement of approximately 300 pM of tyrosine mg-' of muscle 2 h-' was obtained with the concentration of 100 ng ml1 ' of rhIL-I-P. The profile of activity to rhIL-1-P as seen in Figure 4b was obtained in four separate assays and bell-shaped distributions were observed in six assays. The rat diaphragm muscle protein catabolism was not significantly stimulated by IL-1-P in five other assays.
IL-J-P, but not TNF-c, is present in a low molecular weight fraction ofplasma proteins from cancer patients The TNF proteins were not detected in a fraction that containing molecules with lower than 25 kDa obained from cancer plasma samples using L929 cell biossay and the TNF radioimmunoassay. IL--1-P reactive proteins were detected by radioimmunoassay in the plasma/serum of six out of 20 samples analysed. The concentrations ranged from 200 to 380pgml-'. These samples however were not included in muscle proteolysis biossay study, even though the criteria used to select this patient population were the same used for the current study. (Theologides, 1979; Norton et al., 1985) . (Fulks et al., 1975; showing that the increment of tyrosine release from rat diaphragm muscle preparations reflects the net protein degradation, it is most likely that the effect observed is at least in part due to the activation of intracellular protein breakdown. However, such in vitro observations disagree with the results of Lundholm et al. (1981) , which indicate that the net loss of muscle tissue in tumour-bearing animals is more dependent on depressed protein synthesis than breakdown. A third and less likely explanation for the phenomenon is that these factors are causing an enhanced release of tyrosine from the muscle pools.
The biochemical nature of these mediators and their source, whether from tumour or host cells, remains to be determined. In a recent study by Beck and Tisdale (1987) evidence was presented that a 'muscle tissue proteoteolytic factor' is produced by a murine adenocarcinoma of the colon called MAC 16, a tumour selected for its ability to induce severe cachexia in mice. Further evidence that polypeptide factors with similar biological activity are produced by activated macrophages is presented here (Table I) and elsewhere Goldberg et al., 1988; Moldawer et al., 1987) .
IL-1 and TNF, the prominent monocyte/macrophage products can be produced by a variety of tumour cell lines (Busson et al., 1987; Beutler & Cerami, 1986; Spriggs et al., 1987; Dinarello, 1988) . Elevated circulating levels of TNF and IL-1 have been found in patients suffering chronic infection, parasitic and malignant diseases (Beutler & Cerami, 1986; Dinarello, 1988; Moldawer et al., 1988) . In fact, we detected moderate levels of IL-1-P in six of the 20 plasma samples from cancer patients. IL-1 and an IL-1-derived fragment may be the causative agents of accelerated skeletal muscle protein catabolism in febrile patients (Clowes et al., 1983; Baracos et al., 1983; Dinarello et al., 1984) . In agreement with these reports, it was shown here that recombinant human IL-1-o and IL-1-P can stimulate protein catabolism in a rat-diaphragm muscle bioassay. However, we are unable yet to provide a definitive explanation for the variability in the dose-response effect of some assays. We have hypothesised that tissue-released factors might act indirectly by perturbing cellular physiology and responsiveness of muscle tissue to IL-1, as previously described (Wallach et al., 1988) . Despite these facts, the finding that the treatment of cancer samples with the combination of antibodies against human IL-1-< and P partially inhibited the muscle proteolysisinducing activity present in five of the 13 cancer plasma samples examined (Figure 3 ) has further substantiated our evidence that IL-1 can lead muscle tissue to enhance intracellular proteolysis.
TNF, or TNF and IL-1 in a coordinated fashion, can elicit metabolic changes in skeletal muscle tissue (Warren et al., 1987 Fong et al., 1989; Flores et al., 1989) . As a consequence of its active molecular weight being higher than 25 kDa, TNF was not detected in the ultrafiltered fraction of plasma/serum proteins from cancer patients. The results suggest instead that another active factor(s), whose molecular weight is lower than 25 kDa, is acting to accelerate skeletal muscle proteolysis (Figure 3 ). In fact, recent studies have also suggested that another unidentified protein(s) appears to be responsible for accelerating skeletal muscle protein degradation in vitro (Moldawer et al., 1987; Goldberg et al., 1988) . Thus, it is most likely that the induction of muscle protein catabolism which accompanies inflammatory disease is not an effect of a single cytokine, but rather may be mediated by combinations of both cytokines and the classical protein metabolism regulatory hormones: catecholamines, glucagon and glucocorticoids.
Indomethacin, a prostaglandin synthetase inhibitor, decreases the activity of proteolysis-inducing factors and other stimulus leading to in vitro skeletal muscle protein breakdown Rodemann & Goldberg, 1982; Baracos et al., 1983) . In fact, PGE, and PGE2 can affect directly the protein breakdown in skeletal muscle through their capacity to activate the lysosomal enzymes (Rodemann & Goldberg, 1982; . Interestingly, IL-1 by itself or in combination with either polypeptide growth factors or TNF stimulate the local production of PGE2 in many tissues and cell types (Last-Barney et al., 1988; Dinarello, 1988) . Together these findings support our results which show that indomethacin is a potential inhibitor of skeletal muscle protein catabolism activated by polypeptide factors into the plasma samples from cancer patients and by macrophage secretory products.
One particular experiment in this study has shown that the incubation of the rat diaphragm muscle with quin-2, a calcium chelating agent, prevents the acceleration of protein breakdown induced by proteolysis-inducing factors in conditioned medium from macrophage culture. This finding is consistent with previous reports demonstrating that changes in the extracellular and intracellular calcium concentration appear to play a major role in this process (Rodemann & Goldberg, 1982; . Interestingly, studies have indicated that myofibrillar and cytoskeletal proteins in a variety of cells are degraded by a group of cytosolic calcium dependent proteases named calpains (Pontremoli & Melloni, 1986) . Thus, the activation of these enzymes may represent one mechanism by which proteolysis inducing factors produce their effects.
In summary, this study shows that biologically active factors in the plasma of cancer patients and conditioned medium from activated macrophages can enhance in vitro rat skeletal muscle protein catabolism. Indomethacin and quin-2 decreased the activity of these factors suggesting that the activation of protein breakdown and subsequent release of tyrosine is followed by the synthesis of prostaglandins and calcium mobilisation. Although the chemical nature these molecules has yet to be determined, our evidence is consistent with previous studies suggesting that the acceleration of protein catabolism induced by circulating factors might contribute to weight loss and progressive wasting of skeletal muscles in human cancer.
